Ten Stocks Trending on Discord for Thursday September 22, 2022: SPRO, AVCT, SAVA, TSLA, MOHO, SONN, AAPL, FREY, LIDR, GSK
$AAPL
$AVCT
$FREY
$GSK
Computer Manufacturing
Technology
EDP Services
Technology
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 3/23/2026 | $325.00 → $320.00 | Buy | BofA Securities | |
| 3/5/2026 | $267.00 → $268.00 | Neutral | Rosenblatt | |
| 3/4/2026 | $460.00 | Buy | BofA Securities | |
| 3/3/2026 | $239.00 → $248.00 | Underweight | Barclays | |
| 2/25/2026 | $241.00 → $270.00 | Neutral | MoffettNathanson | |
| 2/12/2026 | $550.00 | Buy | Tigress Financial | |
| 2/10/2026 | $325.00 → $340.00 | Outperform | Bernstein | |
| 1/30/2026 | $150.00 → $145.00 | Underweight | Analyst |
BofA Securities reiterated coverage of Apple with a rating of Buy and set a new price target of $320.00 from $325.00 previously
Rosenblatt reiterated coverage of Apple with a rating of Neutral and set a new price target of $268.00 from $267.00 previously
BofA Securities resumed coverage of Tesla with a rating of Buy and set a new price target of $460.00
For Immediate Release: September 17, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a draft guidance, “Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice,” which, when finalized, will support the conduct of randomized controlled trials with streamlined protocols a
For Immediate Release: September 12, 2024 Today, the U.S. Food and Drug Administration authorized the first over-the-counter (OTC) hearing aid software device, Hearing Aid Feature, intended to be used with compatible versions of the Apple AirPods Pro headphones. Once installed and customized to the user’s hearing needs, the Hearing Aid Feature enables compatible versions of the AirPods Pro to serve as an OTC hea
4 - Apple Inc. (0000320193) (Issuer)
4 - Tesla, Inc. (0001318605) (Issuer)
3 - Apple Inc. (0000320193) (Issuer)
Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's licensing partner, GSK announced the FDA had set the PDUFA date as June 18, 2026 Spero estimates cash and cash equivalents as of December 31, 2025 are sufficient to fund current operations into 2028 CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the fourth quarte
Available online around the world, the conference will showcase the latest Apple software and technologies Apple® today announced it will host its annual Worldwide Developers Conference (WWDC) online from June 8-12, bringing developers together from around the world for a week of connection, exploration, and innovation. In addition to the online experience, developers and students will also have the opportunity to celebrate in person during a special event at Apple Park on June 8. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323789514/en/ WWDC26 will spotlight incredible updates for Apple platforms, including AI advanceme
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare di
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
DEF 14A - AEye, Inc. (0001818644) (Filer)
6-K - GSK plc (0001131399) (Filer)
6-K - GSK plc (0001131399) (Filer)
Veteran global marketing leader joins from Meta as Sunbit scales products, partnerships and infrastructure to serve millions more consumers Sunbit, the personalized financial partner for everyday life, today announced the appointment of Shachar G. Scott as Chief Marketing Officer, signaling a pivotal next chapter in the company's growth. Scott brings more than 25 years of experience building and scaling global brands across technology and consumer products with leadership roles at Meta (NASDAQ:META), Apple (NASDAQ:AAPL), Bumble (NASDAQ:BMBL) and Snap (NYSE:SNAP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212757677/en/S
Jennifer Newstead to join Apple as senior vice president, will become general counsel in March 2026 Kate Adams to retire late next year Lisa Jackson to retire Apple® today announced that Jennifer Newstead will become Apple's general counsel on March 1, 2026, following a transition of duties from Kate Adams, who has served as Apple's general counsel since 2017. She will join Apple as senior vice president in January, reporting to CEO Tim Cook and serving on Apple's executive team. In addition, Lisa Jackson, vice president for Environment, Policy, and Social Initiatives, will retire in late January 2026. The Government Affairs organization will transition to Adams, who will oversee the te
This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it
SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)
SC 13G/A - AEye, Inc. (0001818644) (Subject)
SC 13G/A - GSK plc (0001131399) (Subject)
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare di
Revenue Doubled in Q4 over Q3; 40% Commercial Pipeline Expansion; 33% Increase in Customer Count Joining NVIDIA Halos AI Systems Inspection Lab; Demonstrated Apollo™ Lidar with NVIDIA DRIVE AGX Thor™ Operational Runway Into 2028 AEye, Inc. (NASDAQ:LIDR) (the "Company"), a global leader in software-defined, high-performance lidar solutions, today announced financial results for the fourth quarter and full year ended December 31, 2025. Business Highlights NVIDIA Ecosystem Maturity: Joining NVIDIA Halos AI Systems Inspection Lab to bolster automotive product readiness and demonstrated Apollo™ lidar with the NVIDIA DRIVE AGX Thor™ platform, the future centralized brain of NVIDIA-equi
AEye, Inc. (NASDAQ:LIDR), a global leader in software-defined, high-performance lidar solutions, today announced that it will release its 2025 fourth quarter and full year financial results, after market close on Monday, March 16, 2026. A conference call and webcast will be held on the same day, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). During the call, AEye CEO Matt Fisch and CFO Conor Tierney will review the company's financial results and provide a business update, followed by a question-and-answer session. Supplemental financial information will be available on the company's website prior to the conference call. The live webcast of the call with an accompanying slide prese